Condition
Prothrombin G20210A
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07584265Recruiting
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations
NCT07430397Phase 1Recruiting
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
NCT05123326Recruiting
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Showing all 3 trials